PASG
Passage BIO, Inc.
Overview
Passage Bio develops gene therapies for neurodegenerative diseases. The company's lead program, PBFT02, is a one-time gene therapy designed to restore progranulin levels in the brain to treat frontotemporal dementia caused by progranulin deficiency, with expansion into other neurodegenerative conditions including ALS and Alzheimer's disease.
Passage BIO, Inc is a Healthcare company operating in Biotechnology with a $18.3M market cap.
PASG beat consensus EPS by 0.2% in Q1 FY2026, reported May 18, 2026.
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q4 FY2022Earnings2023-03-0623 Q&A exchanges
- Q3 FY2022Earnings2022-11-1015 Q&A exchanges
- Q2 FY2022Earnings2022-08-064 Q&A exchanges
- Q1 FY2022Earnings2022-05-1620 Q&A exchanges
- Q4 FY2021Earnings2022-03-0321 Q&A exchanges
- Q3 FY2021Earnings2021-11-068 Q&A exchanges
- Q2 FY2021Earnings2021-08-0815 Q&A exchanges
- Q1 FY2021Earnings2021-05-0914 Q&A exchanges
History
Earnings history
- Q1 FY20262026-05-18EPS$-2.36 vs $-3.06+22.9%Rev$0 vs ——EODHD
- Q4 FY20252026-03-02EPS$-4.09 vs $-2.80-46.3%Rev$0 vs ——EODHD
- Q3 FY20252025-11-09EPS$-2.44 vs $-0.20-100.0%Rev$0 vs ——EODHD
- Q2 FY20252025-08-11EPS$-2.96 vs $-0.20-100.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.25 vs $-0.22-12.0%Rev$0 vs ——EODHD
- Q4 FY20242025-03-02EPS$-0.20 vs $-0.200.0%Rev$3.2M vs ——EODHD
- Q3 FY20242024-11-10EPS$-0.24 vs $-0.23-2.4%Rev$0 vs ——EODHD
- Q2 FY20242024-08-07EPS$-0.26 vs $-0.31+16.1%Rev$0 vs ——EODHD
- Q1 FY20242024-05-13EPS$-0.30 vs $-0.36+16.7%Rev$0 vs ——EODHD
- Q4 FY20232024-03-03EPS$-0.30 vs $-0.40+25.0%Rev$5.9M vs ——EODHD
- Q3 FY20232023-11-12EPS$-0.49 vs $-0.46-6.5%Rev$0 vs ——EODHD
- Q2 FY20232023-08-06EPS$-0.44 vs $-0.48+8.3%Rev$0 vs ——EODHD
- Q1 FY20232023-05-10EPS$-0.63 vs $-0.50-26.0%Rev$0 vs ——EODHD
- Q4 FY20222023-03-05EPS$-0.49 vs $-0.52+5.8%Rev$0 vs ——EODHD
- Q3 FY20222022-11-09EPS$-0.49 vs $-0.79+38.0%Rev$0 vs ——EODHD
- Q2 FY20222022-08-03EPS$-0.73 vs $-0.83+12.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.79 vs $-0.89+11.2%Rev$0 vs ——EODHD
- Q4 FY20212022-03-02EPS$-0.95 vs $-0.89-6.7%Rev$0 vs ——EODHD
- Q3 FY20212021-11-03EPS$-0.87 vs $-0.86-1.2%Rev$0 vs ——EODHD
- Q2 FY20212021-08-04EPS$-0.90 vs $-0.76-18.4%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-18 | $-2.36 | $-3.06 | +22.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $-4.09 | $-2.80 | -46.3% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-2.44 | $-0.20 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-11 | $-2.96 | $-0.20 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.25 | $-0.22 | -12.0% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-0.20 | $-0.20 | 0.0% | $3.2M | — | — | EODHD |
| Q3 FY2024 | 2024-11-10 | $-0.24 | $-0.23 | -2.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.26 | $-0.31 | +16.1% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.30 | $-0.36 | +16.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-03 | $-0.30 | $-0.40 | +25.0% | $5.9M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.49 | $-0.46 | -6.5% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-06 | $-0.44 | $-0.48 | +8.3% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.63 | $-0.50 | -26.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-05 | $-0.49 | $-0.52 | +5.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.49 | $-0.79 | +38.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-03 | $-0.73 | $-0.83 | +12.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.79 | $-0.89 | +11.2% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-02 | $-0.95 | $-0.89 | -6.7% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-03 | $-0.87 | $-0.86 | -1.2% | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-04 | $-0.90 | $-0.76 | -18.4% | $0 | — | — | EODHD |
Source: EODHD. PASG reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks PASG's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $3.63 | $3.10 | +17.1% | +6.8% | +5.5% |
| Q4 FY2022 | $3.96 | $3.15 | +25.6% | +3.3% | +2.2% |
| Q3 FY2022 | $3.73 | $3.28 | +13.8% | +1.0% | +1.6% |
| Q2 FY2022 | $4.03 | $3.20 | +25.8% | +4.9% | +6.8% |
| Q1 FY2021 | $3.72 | $3.13 | +19.0% | -4.8% | -2.7% |
| Q4 FY2021 | $4.25 | $3.38 | +25.6% | -4.3% | -5.8% |
| Q3 FY2021 | $3.89 | $3.34 | +16.5% | -0.9% | -1.7% |
| Q2 FY2021 | $3.90 | $3.20 | +21.9% | +5.4% | +2.5% |
| Q1 FY2020 | $3.82 | $3.40 | +12.4% | +5.1% | +2.8% |
| Q4 FY2020 | $4.36 | $3.40 | +28.3% | -4.3% | -4.3% |
Guidance change history
Sample- Q1 FY2022Raised2022-04-15
- Q4 FY2022Raised2022-13-15
- Q3 FY2022Raised2022-10-15
- Q2 FY2022Raised2022-07-15
- Q1 FY2021Raised2021-04-15
- Q4 FY2021Raised2021-13-15
- Q3 FY2021Raised2021-10-15
- Q2 FY2021Raised2021-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- William ChouCEO1 yr 5 mo2 callsCurrentSample
CEO since 2025 • 1/2 beats (50%) • guidance suspended Q2 FY2022
- Kathleen BorthwickCFO1 yr 5 mono recorded callsCurrentSample
CFO since 2025 • 1/2 beats (50%) • last call held guidance Q1 FY2022
- Edgar B CaleGC & CORPORATE SECRETARY6 mo1 callFormerSample
OTHER since 2024 • 2/2 beats (100%) • guidance suspended Q1 FY2022
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for PASG.
$ curl https://api.spokenalpha.com/v1/companies/PASGFAQ
Frequently asked about PASG
Where can I find Passage BIO, Inc.'s (PASG) earnings call transcripts?
Spoken Alpha indexes PASG's earnings call transcripts at https://spokenalpha.com/companies/PASG. Each call links to attributed speakers and parsed analyst Q&A. Passage BIO, Inc.'s own investor relations page is at https://www.passagebio.com/investors-and-news/overview/default.aspx.
When was Passage BIO, Inc.'s most recent earnings call?
Passage BIO, Inc. (PASG) held its most recent earnings call on 2023-03-06, covering fiscal Q4 2022.
What sector is PASG in?
Passage BIO, Inc. (PASG) operates in the Healthcare sector (Biotechnology industry).